Pharmacological Treatment of Neuropsychiatric Symptoms in Huntington’s Disease: A Systematic Review
Abstract Background: Studies focusing on the treatment of neuropsychiatric symptoms (NPS) in Huntington’s disease (HD) are scarce and show a…
Huntington's disease
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice
Abstract Background: Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in…
Amyloid modifier SERF1a interacts with polyQ-expanded huntingtin-exon 1 via helical interactions and exacerbates polyQ-induced toxicity
Abstract Abnormal polyglutamine (polyQ) expansion and fibrillization occur in Huntington’s disease (HD). Amyloid modifier SERF enhances amyloid formation, but the…
Small molecules to perform big roles: The search for Parkinson’s and Huntington’s disease therapeutics
Abstract Neurological motor disorders (NMDs) such as Parkinson’s disease and Huntington’s disease are characterized by the accumulation and aggregation of…
A systematic review of minor phytocannabinoids with promising neuroprotective potential
Abstract Embase and PubMed were systematically searched for articles addressing the neuroprotective properties of phytocannabinoids, apart from cannabidiol and Δ9‐tetrahydrocannabinol,…
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Abstract Movement disorders such as Parkinson’s disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When…